(WASHINGTON – August 4, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The findings suggest that underuse of these drugs may help explain why MDS outcomes have not improved over the past two decades since these life-extending medications became available.  

A new study by researchers at the Icahn School of Medicine at Mount Sinai finds that widely used AI chatbots are highly vulnerable to repeating and elaborating on false medical information, revealing a critical need for stronger safeguards before these tools can be trusted in health care. The researchers also demonstrated that a simple built-in warning prompt can meaningfully reduce that risk, offering a practical path forward as the technology rapidly evolves. Their findings were detailed in the August 2 online issue of Communications Medicine [https://doi.org/10.1038/s43856-025-01021-3].